Related references
Note: Only part of the references are listed.Roflumilast n-oxide associated with PGE2 prevents the neutrophil elastase-induced production of chemokines by epithelial cells
Tatiana Victoni et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2016)
Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis
Jian Luo et al.
RESPIRATORY RESEARCH (2016)
A Randomized, Placebo-controlled Trial of Roflumilast Effect on Proline-Glycine-Proline and Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease
J. Michael Wells et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Diagnosis and Pharmacotherapy of Stable Chronic Obstructive Pulmonary Disease: The Finnish Guidelines
Hannu Kankaanranta et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2015)
Quantitative benefit-harm assessment for setting research priorities: the example of roflumilast for patients with COPD
Milo A. Puhan et al.
BMC MEDICINE (2015)
Prevention of Acute Exacerbations of COPD American College of Chest Physicians and Canadian Thoracic Society Guideline
Gerard J. Criner et al.
CHEST (2015)
Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives
Mario Cazzola et al.
DRUGS (2015)
Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial
Fernando J. Martinez et al.
LANCET (2015)
Cross-talk between PKA-Cβ and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi
Seiko Susuki-Miyata et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Roflumilast for asthma: Weighing the evidence
E. D. Bateman et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2015)
Roflumilast added to triple therapy in patients with severe COPD: A real life study
Mariana Munoz-Esquerre et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2015)
A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world
Yin Wan et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2015)
Lower 30-day readmission rates with roflumilast treatment among patients hospitalized for chronic obstructive pulmonary disease
Alex Z. Fu et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2015)
Roflumilast partially reverses smoke-induced mucociliary dysfunction
Andreas Schmid et al.
RESPIRATORY RESEARCH (2015)
Effect of a Dose-Escalation Regimen for Improving Adherence to Roflumilast in Patients with Chronic Obstructive Pulmonary Disease
Hyunjung Hwang et al.
TUBERCULOSIS AND RESPIRATORY DISEASES (2015)
Roflumilast for the Treatment of COPD in an Asian Population A Randomized, Double-Blind, Parallel-Group Study
Jinping Zheng et al.
CHEST (2014)
Counterpoint: Were Industry-Sponsored Roflumilast Trials Appropriate? No
Jason Rho et al.
CHEST (2014)
Point: Were Industry-Sponsored Roflumilast Trials Appropriate? Yes
Samy Suissa et al.
CHEST (2014)
Phosphodiesterase Inhibitors for Chronic Obstructive Pulmonary Disease: What Does the Future Hold?
Maria Gabriella Matera et al.
DRUGS (2014)
The effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients
Wilfried De Backer et al.
EUROPEAN RESPIRATORY JOURNAL (2014)
PDE inhibitors currently in early clinical trials for the treatment of asthma
Maria Gabriella Matera et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
Roflumilast: the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD
Donald P. Tashkin
EXPERT OPINION ON PHARMACOTHERAPY (2014)
Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease
Javier Milara et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Defining Phenotypes in COPD: An Aid to Personalized Healthcare
Andrea Segreti et al.
MOLECULAR DIAGNOSIS & THERAPY (2014)
Advances in targeting cyclic nucleotide phosphodiesterases
Donald H. Maurice et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Roflumilast N-Oxide Prevents Cytokine Secretion Induced by Cigarette Smoke Combined with LPS through JAK/STAT and ERK1/2 Inhibition in Airway Epithelial Cells
Tatiana Victoni et al.
PLOS ONE (2014)
Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD
Nicola A. Hanania et al.
RESPIRATORY MEDICINE (2014)
Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: A meta-analysis
Jun-Hong Yan et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2014)
Survival of patients with small cell lung cancer undergoing lung resection in England, 1998-2009
Margreet Luechtenborg et al.
THORAX (2014)
The clinical and integrated management of COPD. An official document of AIMAR (Interdisciplinary Association for Research in Lung Disease), AIPO (Italian Association of Hospital Pulmonologists), SIMER (Italian Society of Respiratory Medicine), SIMG (Italian Society of General Medicine)
Germano Bettoncelli et al.
MULTIDISCIPLINARY RESPIRATORY MEDICINE (2014)
Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom
Yevgeniy Samyshkin et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2014)
Phosphodiesterase-4 Inhibitor Therapy for Lung Diseases
Bianca Beghe et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Chronic Obstructive Pulmonary Disease: Official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care
Vladimir Koblizek et al.
BIOMEDICAL PAPERS-OLOMOUC (2013)
Cardiovascular Safety in Patients Receiving Roflumilast for the Treatment of COPD
William B. White et al.
CHEST (2013)
Efficacy of Roflumilast in the COPD Frequent Exacerbator Phenotype
Jadwiga A. Wedzicha et al.
CHEST (2013)
Phenotyping the heterogeneity of chronic obstructive pulmonary disease
Bethan L. Barker et al.
CLINICAL SCIENCE (2013)
Inhaled corticosteroids for chronic obstructive pulmonary disease
Mario Cazzola et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Application of population pharmacokinetic modeling to explore the impact of alternative roflumilast dosing regimens on tolerability
Gezim Lahu et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2013)
Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease
Peter J. Barnes
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Roflumilast Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor-α and Chemokine Production by Human Lung Parenchyma
Amparo Buenestado et al.
PLOS ONE (2013)
Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland
Yevgeniy Samyshkin et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2013)
Does roflumilast improve dyspnea in patients with chronic obstructive pulmonary disease? A meta-analysis
Lei Pan et al.
JOURNAL OF THORACIC DISEASE (2013)
Spanish COPD Guidelines (GesEPOC): Pharmacological treatment of stable COPD
Marc Miravitlles et al.
ATENCION PRIMARIA (2012)
Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro
J. Milara et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide
A. Buenestado et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Selective PDE inhibitors as novel treatments for respiratory diseases
Clive P. Page et al.
CURRENT OPINION IN PHARMACOLOGY (2012)
Physiological effects of roflumilast at rest and during exercise in COPD
Denis E. O'Donnell et al.
EUROPEAN RESPIRATORY JOURNAL (2012)
Sensitive quantification of roflumilast and roflumilast N-oxide in human plasma by LC-MS/MS employing parallel chromatography and electrospray ionisation
Norbert G. Knebel et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2012)
Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis
Yuji Oba et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2012)
Acute Exacerbations of Chronic Obstructive Pulmonary Disease Identification of Biologic Clusters and Their Biomarkers
Mona Bafadhel et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease
Klaus F. Rabe
BRITISH JOURNAL OF PHARMACOLOGY (2011)
S-Adenosylmethionine Decreases Lipopolysaccharide-Induced Phosphodiesterase 4B2 and Attenuates Tumor Necrosis Factor Expression via cAMP/Protein Kinase A Pathway
Leila Gobejishvili et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Roflumilast in Asian patients with COPD: A randomized placebo-controlled trial
Sang-Do Lee et al.
RESPIROLOGY (2011)
Protease-activated receptor 2 activation of myeloid dendritic cells regulates allergic airway inflammation
Ian P. Lewkowich et al.
RESPIRATORY RESEARCH (2011)
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis
P. H. Schafer et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Population Pharmacokinetic Modelling of Roflumilast and Roflumilast N-Oxide by Total Phosphodiesterase-4 Inhibitory Activity and Development of a Population Pharmacodynamic-Adverse Event Model
Gezim Lahu et al.
CLINICAL PHARMACOKINETICS (2010)
Roflumilast in chronic obstructive pulmonary disease: evidence from large trials
Mario Cazzola et al.
EXPERT OPINION ON PHARMACOTHERAPY (2010)
Phosphodiesterase 4B is essential for TH2-cell function and development of airway hyperresponsiveness in allergic asthma
S. -L. Catherine Jin et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
The human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4D
F. Mori et al.
JOURNAL OF CHEMICAL NEUROANATOMY (2010)
The preclinical pharmacology of roflumilast - A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease
Armin Hatzelmann et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2010)
Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown
Miles D. Houslay
TRENDS IN BIOCHEMICAL SCIENCES (2010)
The divergent opinions of regulatory authorities on roflumilast are puzzling but we need new drugs for treating chronic obstructive pulmonary disease
Mario Cazzola
Therapeutic Advances in Respiratory Disease (2010)
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials
Leonardo M. Fabbri et al.
LANCET (2009)
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
Peter M. A. Calverley et al.
LANCET (2009)
A major functional role for phosphodiesterase 4D5 in human airway smooth muscle cells
Charlotte K. Billington et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2008)
Outcomes for COPD pharmacological trials:: from lung function to biomarkers
M. Cazzola et al.
EUROPEAN RESPIRATORY JOURNAL (2008)
Effect of roflumilast on inflammatory cells in the lungs of cigarette smoke-exposed mice
Piero A Martorana et al.
BMC Pulmonary Medicine (2008)
Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD
Diana C. Grootendorst et al.
THORAX (2007)
Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability
M-J Sanz et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease
Peter M. A. Calverley et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Phosphodiesterase type 4 inhibitors cause proinflammatory effects in vivo
Kerryn McCluskie et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Phosphodiesterase inhibitors in airways disease
KF Chung
EUROPEAN JOURNAL OF PHARMACOLOGY (2006)
Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-κB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation
HJ Kwak et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke
PA Martorana et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Roflumilast -: an oral anti-inflammatory treatment for chronic obstructive pulmonary disease:: a randomised controlled trial
KF Rabe et al.
LANCET (2005)
Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial
EFM Wouters et al.
THORAX (2005)
Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells
M Mata et al.
THORAX (2005)
The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro
NA Jones et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2005)
Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease
BJ Lipworth
LANCET (2005)
Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers
R Barber et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2004)
PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization
MD Houslay et al.
BIOCHEMICAL JOURNAL (2003)
Share Paper
